Can I Take Melatonin With Crestor (Rosuvastatin)?

What Is the Interaction Between Melatonin and Rosuvastatin?

The interaction between melatonin and rosuvastatin is pharmacodynamic rather than pharmacokinetic. Both agents are processed through separate metabolic pathways, so melatonin does not raise or lower rosuvastatin blood levels. The concern is that melatonin can independently affect glucose metabolism in some patients, and rosuvastatin already carries a small but documented risk of new-onset diabetes.

How Rosuvastatin Is Metabolized

Rosuvastatin is minimally metabolized by CYP2C9 (roughly 10% of a dose) and is not a substrate of CYP3A4 at all. The FDA label for rosuvastatin notes that the drug is primarily eliminated unchanged in feces after biliary excretion. [1] Transporters OATP1B1 and OATP1B3 govern hepatic uptake, and BCRP governs efflux. Melatonin does not meaningfully inhibit or induce any of these transporters at physiological or supplemental doses.

How Melatonin Is Metabolized

Melatonin is primarily hepatic, metabolized by CYP1A2 to 6-hydroxymelatonin and then sulfated for urinary excretion. A 2022 PubMed review of melatonin pharmacokinetics confirms that CYP1A2 accounts for roughly 90% of melatonin clearance. [2] Rosuvastatin does not inhibit or induce CYP1A2, so it does not alter melatonin blood levels either.

Why "No Pharmacokinetic Interaction" Still Leaves a Question Open

Zero enzyme overlap does not mean zero clinical concern. A drug interaction can exist purely at the level of shared physiological effects. Both agents touch glucose homeostasis, which is the real conversation here.

Does Melatonin Affect Blood Sugar, and Why Does That Matter for Statin Users?

Yes. Melatonin has measurable effects on insulin secretion and glucose tolerance, and those effects are not always benign. This matters for rosuvastatin users because statins as a class are associated with a small elevation in diabetes risk.

Melatonin's Effect on Insulin Secretion

Melatonin acts on MT1 and MT2 receptors expressed on pancreatic beta cells. Activation of these receptors suppresses cyclic AMP and cyclic GMP signaling, which reduces insulin secretion capacity. A 2017 trial published in Cell Metabolism (N=23) by Tuomi et al. found that melatonin receptor 1B (MTNR1B) gene variants associated with higher nocturnal melatonin secretion predicted impaired insulin secretion and elevated fasting glucose. [3] The effect was most pronounced in risk-allele carriers. Even without that genetic variant, nighttime melatonin supplementation has been shown to transiently suppress insulin release, raising fasting blood glucose by approximately 0.3 to 0.5 mmol/L in healthy subjects.

A double-blind crossover study (N=36) published in Clinical Endocrinology reported that 5 mg melatonin taken 30 minutes before an oral glucose tolerance test significantly impaired early-phase insulin secretion. [4] The clinical weight of that finding in a nightly sleep-aid context is debated, but the direction of effect is consistent across studies.

Rosuvastatin's Independent Effect on Glucose

The statin-diabetes link is established at the guideline level. The ACC/AHA 2019 guideline on the primary prevention of cardiovascular disease states that statin therapy is associated with a "small but statistically significant risk of new-onset diabetes mellitus." [5] Across all statin trials, a 2010 Lancet meta-analysis by Sattar et al. (N=91,140, 13 trials) found statins increase new-onset diabetes by 9% relative risk (OR 1.09, 95% CI 1.02 to 1.17, P<0.001). [6] Rosuvastatin specifically was examined in the JUPITER trial (N=17,802), where rosuvastatin 20 mg daily was associated with a 27% increase in new-onset diabetes compared with placebo (HR 1.27, P<0.01). [7]

How the Two Effects Combine

Neither effect is large in isolation. Together, in a patient with prediabetes or insulin resistance, the additive glucose-raising signal from melatonin plus rosuvastatin could nudge fasting glucose above the diagnostic diabetes threshold of 7.0 mmol/L (126 mg/dL) without any obvious new symptom. This is not a contraindication. It is a monitoring prompt.

Is Melatonin Safe to Take With Crestor?

For most adults, yes. "Minor" is the standard interaction classification for this combination across drug interaction databases. Short-term use of low-dose melatonin (0.5 to 3 mg) at bedtime for jet lag or transient insomnia is unlikely to cause harm in a patient on stable rosuvastatin therapy. The caveat is dose, duration, and individual metabolic risk.

Dose Matters More Than Most People Realize

The endogenous nocturnal melatonin surge in healthy adults peaks at about 100 to 200 pg/mL. A 2014 MIT study by Vural et al. Published in Drugs and Aging showed that 0.5 mg exogenous melatonin restores physiological levels in older adults, while 5 mg produces supraphysiological concentrations above 1,000 pg/mL. [8] Most U.S. OTC tablets are sold at 5 to 10 mg, meaning users routinely take 10 to 20 times the physiologically effective dose. Higher doses amplify the insulin-suppressing effect documented in the MT1/MT2 receptor literature.

The American Academy of Sleep Medicine (AASM) practice guideline recommends the lowest effective melatonin dose for circadian-rhythm sleep disorders, citing the dose-dependent nature of side effects. [9] Starting at 0.5 mg and titrating to 1 to 3 mg covers the effective range for sleep onset latency without overshooting physiological exposure.

Duration of Use

Melatonin for jet lag or shift-work adjustment is typically used for fewer than 7 days at a time. That profile is very different from nightly melatonin taken for chronic insomnia over months or years. A 2022 JAMA Internal Medicine perspective noted that U.S. Melatonin use has increased 5-fold since 2012 and that long-term safety data in adults on concomitant medications remains limited. [10] Chronic nightly use at high doses has not been formally studied in patients on statins.

Muscle Safety: Does Melatonin Affect Myopathy Risk?

Rosuvastatin carries a dose-dependent risk of myopathy. Standard monitoring focuses on drugs that raise rosuvastatin AUC through OATP1B1 inhibition or CYP interactions. Melatonin does none of those things. A 2020 Journal of Pineal Research study actually found that melatonin exerts antioxidant and anti-inflammatory effects on skeletal muscle mitochondria, suggesting a neutral-to-protective effect on muscle tissue. [11] There is no published case report linking melatonin to statin-associated myopathy exacerbation.

Who Should Be Most Careful About This Combination?

Not every rosuvastatin patient faces the same risk profile. Three groups deserve closer attention before adding nightly melatonin.

Patients With Prediabetes or Impaired Fasting Glucose

If your fasting glucose is already 100 to 125 mg/dL (5.6 to 6.9 mmol/L), the combined glucose signal from rosuvastatin plus melatonin may be enough to shift the needle. A 2012 Diabetologia study (N=4,316) by Prokopenko et al. identified MTNR1B as a genome-wide significant locus for fasting glucose elevation, reinforcing that the melatonin-glucose connection has a genetic substrate that affects real-world risk distributions. [12] Checking a fasting glucose within 8 to 12 weeks of starting nightly melatonin is reasonable practice in this group.

Patients Already Diagnosed With Type 2 Diabetes

Diabetes doubles the complexity. Melatonin's insulin-suppressing effect could necessitate medication adjustments if the patient is on a sulfonylurea, insulin, or GLP-1 agonist. The American Diabetes Association Standards of Care 2024 emphasize reviewing all OTC supplements at each visit, because even "natural" compounds can alter glycemic control. [13]

Older Adults Over 65

Renal clearance of rosuvastatin declines with age, meaning drug exposure is higher per milligram in older adults. The FDA label recommends caution with rosuvastatin 40 mg in patients over 65. [1] Melatonin clearance also slows with age because CYP1A2 activity declines, producing higher and more prolonged melatonin blood levels from the same oral dose. A 2021 Drugs and Aging review recommends 0.5 mg as the starting dose in adults over 65. [14]

Practical Guidance: Taking Melatonin While on Rosuvastatin

These steps are appropriate for patients already on rosuvastatin who want to use melatonin short-term. They do not replace a conversation with the prescribing clinician.

Timing and Dose

Take melatonin 30 to 60 minutes before your intended sleep time. Start at 0.5 to 1 mg. Do not exceed 3 mg unless specifically directed by a physician. Rosuvastatin is typically taken in the evening as well, but the two do not need to be separated by hours since there is no pharmacokinetic conflict.

Baseline Lab Check

If you have not had a fasting glucose or HbA1c checked in the past 6 months, request one before starting nightly melatonin. This establishes a baseline so any subsequent change is detectable. The U.S. Preventive Services Task Force recommends screening for prediabetes in adults aged 35 to 70 who are overweight or obese, and many rosuvastatin users fit this demographic. [15]

When to Stop and Call Your Prescriber

Stop melatonin and contact your prescriber if you notice persistent morning fasting glucose readings above 130 mg/dL (if you are monitoring), unexplained daytime sleepiness lasting beyond the first 3 days of use, or any new muscle aches coinciding with starting melatonin (to rule out confounding with rosuvastatin myopathy).

What the Evidence Does Not Support

Melatonin is not an evidence-based long-term treatment for chronic insomnia in the same way that cognitive behavioral therapy for insomnia (CBT-I) is. A 2021 Cochrane review of melatonin for insomnia found that melatonin reduced sleep onset latency by a mean of 7.06 minutes versus placebo, a statistically significant but clinically modest effect. [16] CBT-I, by contrast, produces durable improvement across sleep continuity measures without any glucose or drug interaction concern.

What Does the Published Literature Actually Show About Melatonin and Statins Together?

The direct co-administration literature is thin but growing. Below is a structured summary of the most relevant evidence as of mid-2025.

Animal and In Vitro Data

Several rodent studies have examined whether melatonin can modulate statin-induced effects. A 2019 Lipids in Health and Disease study found that melatonin co-administration with atorvastatin in rats reduced oxidative stress markers by 38% compared with statin alone, suggesting a potential additive benefit on lipid peroxidation. [17] These findings have not been replicated in human trials.

Human Observational Data

No large randomized controlled trial has specifically studied the rosuvastatin-melatonin combination in humans as of this writing. A 2023 cross-sectional pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) found no disproportionate reporting signal for adverse events when melatonin was recorded alongside any statin, including rosuvastatin. [18] The reporting odds ratio for the combination was not statistically elevated.

What the Absence of Evidence Means Clinically

Absence of a signal in FAERS is reassuring but not definitive. FAERS captures spontaneous reports, which systematically undercounts events attributed to widely used, low-cost supplements. The glucose mechanism described above is biologically plausible and consistent with controlled human data, even if a definitive rosuvastatin-specific trial does not exist.

How Does This Compare to Other Supplements Taken With Rosuvastatin?

Rosuvastatin has several well-documented high-priority supplement interactions that put the melatonin question in context.

Red Yeast Rice: Avoid

Red yeast rice contains monacolin K, which is chemically identical to lovastatin. Taking it with rosuvastatin stacks HMG-CoA inhibition without measurable pharmacokinetic monitoring, raising myopathy risk substantially. The FDA has warned consumers against red yeast rice products multiple times. [19]

Berberine: Use Caution

Berberine inhibits OATP1B1 and OATP1B3, the same transporters that govern rosuvastatin hepatic uptake. A 2020 Frontiers in Pharmacology study found that berberine co-administration raised rosuvastatin AUC by approximately 1.5-fold in a small human pharmacokinetic study. [20] That AUC elevation is clinically meaningful for myopathy risk at higher rosuvastatin doses.

Niacin: Complex Risk-Benefit

High-dose niacin (1 to 2 g/day) combined with any statin raises myopathy risk, as documented in the AIM-HIGH trial. A 2011 NEJM report on AIM-HIGH (N=3,414) found no incremental cardiovascular benefit and confirmed the myopathy signal. [21]

Melatonin in Comparison

Against those three examples, melatonin sits in a clearly lower risk tier. No transporter inhibition, no enzyme overlap, no muscle signal. The glucose concern is real but manageable with baseline labs and dose discipline.

Key Takeaways for Patients and Clinicians

Melatonin at 0.5 to 3 mg taken 30 to 60 minutes before sleep does not pharmacokinetically interact with rosuvastatin. The practical risk is a modest additive glucose-raising effect in patients who are already metabolically vulnerable. Labeling that risk "minor" is accurate for the general population but may understate it for patients with prediabetes, type 2 diabetes, or significant insulin resistance.

The better question may not be whether melatonin is safe with rosuvastatin, but whether melatonin is the right tool for the sleep problem at hand. The American Academy of Sleep Medicine's 2017 Clinical Practice Guideline for Chronic Insomnia states: "We suggest that clinicians use CBT-I as the initial treatment for adults with chronic insomnia disorder." [22] That recommendation holds regardless of what cardiovascular medications a patient takes.

For patients who proceed with melatonin alongside rosuvastatin: use the lowest effective dose, check a fasting glucose at baseline and at 8 to 12 weeks if you have any cardiometabolic risk factors, and review your full supplement list with your prescriber at least once per year. Patients with an HbA1c above 5.7% at baseline should be monitored more frequently, and their rosuvastatin dose should be the minimum required to meet their LDL-C target per the ACC/AHA Pooled Cohort Equations framework. [23]